Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
Total Valuation
Ascendis Pharma has a market cap or net worth of $10.45B. The enterprise value is $9.49B.
Market Cap$10.45B
Enterprise Value$9.49B
Share Statistics
Ascendis Pharma has 60,970,566 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,970,566
Owned by Insiders―
Owned by Institutions0.15%
Financial Efficiency
Ascendis Pharma’s return on equity (ROE) is 3.58 and return on invested capital (ROIC) is -37.00%.
Return on Equity (ROE)3.58
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-37.00%
Return on Capital Employed (ROCE)-1.03
Revenue Per Employee357.56K
Profits Per Employee-371.76K
Employee Count1,017
Asset Turnover0.31
Inventory Turnover0.15
Valuation Ratios
The current PE Ratio of Ascendis Pharma is -20.36. Ascendis Pharma’s PEG ratio is -2.42.
PE Ratio-20.36
PS Ratio0.00
PB Ratio-47.99
Price to Fair Value-72.81
Price to FCF-29.78
Price to Operating Cash Flow-29.75
PEG Ratio-2.42
Income Statement
In the last 12 months, Ascendis Pharma had revenue of 363.64M and earned -378.08M in profits. Earnings per share was -6.53.
Revenue363.64M
Gross Profit319.38M
Operating Income-278.76M
Pretax Income-373.24M
Net Income-378.08M
EBITDA-290.02M
Earnings Per Share (EPS)-6.53
Cash Flow
In the last 12 months, operating cash flow was -250.07M and capital expenditures -924.00K, giving a free cash flow of -250.99M billion.
Operating Cash Flow-250.07M
Free Cash Flow-250.99M
Free Cash Flow per Share-4.12
Dividends & Yields
Ascendis Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.83
52-Week Price Change31.24%
50-Day Moving Average159.59
200-Day Moving Average142.26
Relative Strength Index (RSI)59.76
Average Volume (3m)483.73K
Important Dates
Ascendis Pharma upcoming earnings date is Sep 9, 2025, TBA Not Confirmed.
Last Earnings DateMay 1, 2025
Next Earnings DateSep 9, 2025
Ex-Dividend Date―
Financial Position
Ascendis Pharma as a current ratio of 1.17, with Debt / Equity ratio of -446.39%
Current Ratio1.17
Quick Ratio0.84
Debt to Market Cap0.11
Net Debt to EBITDA-1.02
Interest Coverage Ratio-4.26
Taxes
In the past 12 months, Ascendis Pharma has paid 4.84M in taxes.
Income Tax4.84M
Effective Tax Rate-0.01
Enterprise Valuation
Ascendis Pharma EV to EBITDA ratio is -27.56, with an EV/FCF ratio of -25.99.
EV to Sales21.98
EV to EBITDA-27.56
EV to Free Cash Flow-25.99
EV to Operating Cash Flow-26.11
Balance Sheet
Ascendis Pharma has $559.54M in cash and marketable securities with €856.62M in debt, giving a net cash position of $297.07M billion.
Cash & Marketable Securities$559.54M
Total Debt€856.62M
Net Cash$297.07M
Net Cash Per Share$4.87
Tangible Book Value Per Share-$1.90
Margins
Gross margin is 85.30%, with operating margin of -76.66%, and net profit margin of -103.97%.
Gross Margin85.30%
Operating Margin-76.66%
Pretax Margin-102.64%
Net Profit Margin-103.97%
EBITDA Margin-79.76%
EBIT Margin-84.63%
Analyst Forecast
The average price target for Ascendis Pharma is $224.92, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$224.92
Price Target Upside29.90% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast10.69%
EPS Growth Forecast34.71%